Osteoprotegerin, Fibroblast Growth Factor 23, and Vitamin D3 Levels in Male Patients with Hypogonadism

Abstract

Cardiometabolic disorders and osteoporosis are prevalent in patients with hypogonadism. Osteoprotegerin (OPG) and fibroblast growth factor-23 (FGF-23), are co-secreted from bones and vascular endothelium, regulating bone mineral metabolism and vascular functions. Vitamin D is another hormone with dual effects on bone and vascular metabolism. The aim of this study was to search for any difference between the serum levels of OPG, FGF-23, and vitamin D in patients with hypogonadism and the healthy controls. We also aimed to search for any relationship between these parameters and endothelial dysfunction or insulin resistance. Forty-nine male patients with congenital hypogonadotropic hypogonadism (CHH) (mean age 20.71±1.75 years) and 43 BMI matched healthy male subjects (mean age 21.37±1.04 years) were enrolled. OPG, FGF-23, vitamin D, and asymmetric dimethylarginine (ADMA) levels were measured from the fasting serum samples. The insulin sensitivity was estimated by homeostatic model assessment-insulin resistance (HOMA-IR) formula. Triglycerides, insulin, HOMA-IR, and ADMA levels in the patient group were significantly higher than the values of the control group (p=0.014, p=0.002, p=0.003, p<0.001, respectively). The OPG, FGF-23, and vitamin D levels of the patients were not significantly different from the healthy controls. In addition, these markers were not correlated to ADMA or HOMA-IR levels. The results show that young and treatment naive subjects with CHH have endothelial dysfunction and insulin resistance when compared to their healthy counterparts. However, the OPG, FGF-23, and vitamin D levels were similar in the 2 groups. In addition, these parameters are not significantly related to the endothelial functions or insulin resistance in these subjects.

Key words

hypogonadism - asymmetric dimethyl arginine - osteoprotegerin - fibroblast growth factor-23 - vitamin D3

• References

• 1 Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559
• 2 Ferlin A, Schipilliti M, Di Mambro A, Vinanzi C, Foresta C. Osteoporosis in Klinefelter’s syndrome. Mol Hum Reprod 2010; 16: 402-410
• 3 Francis RM, Peacock M, Aaron JE, Selby PL, Taylor GA, Thompson J, Marshall DH, Horsman A. Osteoporosis in hypogonadal men: role of decreased plasma 1,25-dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 1986; 7: 261-268
• 4 Dupree K, Dobs A. Osteopenia and male hypogonadism. Rev Urol 2004; 6 (Suppl. 06) S30-S34
• 5 Jackson JA, Kleerekoper M, Parfitt AM, Rao DS, Villanueva AR, Frame B. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53-58
• 6 Laitinen EM, Hero M, Vaaralahti K, Tommiska J, Raivio T. Bone mineral density, body composition and bone turnover in patients with congenital hypogonadotropic hypogonadism. Int J Androl 2012; 35: 534-540
• 7 Bojesen A, Birkebaek N, Kristensen K, Heickendorff L, Mosekilde L, Christiansen JS, Gravholt CH. Bone mineral density in Klinefelter syndrome is reduced and primarily determined by muscle strength and resorptive markers, but not directly by testosterone. Osteoporos Int 2011; 22: 1441-1450
• 8 Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 2006; 91: 843-850
• 9 Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts Male Aging Study. Diabetes Care 2000; 23: 490-494
• 10 Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone binding globulin predict the metabolic syndrome and diabetes mellitus in middle-aged men. Diabetes Care 2004; 27: 1036-1041
• 11 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
• 12 Sonmez A, Haymana C, Bolu E, Aydogdu A, Tapan S, Serdar M, Altun B, Barcin C, Taslipinar A, Meric C, Uckaya G, Kutlu M. Metabolic syndrome and the effect of testosterone treatment in young men with congenital hypogonadotropic hypogonadism. Eur J Endocrinol 2011; 164: 759-764
• 13 Cersosimo E, DeFronzo RA. Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases. Diabetes Metab Res Rev 2006; 22: 423-436
• 14 Gast KB, Tjeerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. PLoS One 2012; 7: e52036
• 15 Böger RH, Maas R, Schulze F, Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality – an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009; 60: 481-487
• 16 Cakir E, Ozcan O, Yaman H, Akgul EO, Bilgi C, Erbil MK, Yesilova Z. Elevated plasma concentration of asymmetric dimethylarginine that is reduced by single dose testosterone administration in idiopathic hypogonadotropic hypogonadism patients. J Clin Endocrinol Metab 2005; 90: 1651-1654
• 17 Raggi P, Giachelli C, Bellasi A. Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis. Nat Clin Pract Cardiovasc Med 2007; 4: 26-33
• 18 Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe?. Nephrol Dial Transplant 2010; 25: 1376-1381
• 19 Zoccali C, Yilmaz MI, Mallamaci F. FGF23: a mature renal and cardiovascular risk factor?. Blood Purif 2013; 36: 52-57
• 20 Yilmaz MI, Sonmez A, Saglam M, Yaman H, Kilic S, Turker T, Unal HU, Gok M, Cetinkaya H, Eyileten T, Oguz Y, Caglar K, Vural A, Mallamaci F, Zoccali C. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol 2013; 37: 126-134
• 21 Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Bostrom K, Demer LL. Multilineage potential of cells from the artery wall. Circulation 2003; 108: 2505-2510
• 22 Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol 1999; 141: 195-210
• 23 Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 2001; 86: 631-637
• 24 Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 2004; 109: 2175-2180
• 25 Venuraju SM, Yerramasu A, Corder R, Lahiri A. Osteoprotegerin as a Predictor of Coronary Artery Disease and Cardiovascular Mortality and Morbidity. J Am Coll Cardiol 2010; 55: 2049-2061
• 26 Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357: 266-281
• 27 London GM, Guérin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Mëtivier F. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25- hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18: 613-620
• 28 Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and metaanalysis. J Clin Endocrinol Metab 2007; 92: 2017-2029
• 29 Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin D is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990–2000. Diabetes 2008; 57: 2619-2625
• 30 Burnett-Bowie SM, Mendoza N, Leder BZ. Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone 2007; 40: 913-918
• 31 Pepene CE, Crişan N, Coman I. Elevated serum receptor activator of nuclear factor kappa B ligand and osteoprotegerin levels in late-onset male hypogonadism. Clin Invest Med 2011; 34: E232
• 32 Lee DM, Tajar A, Pye SR, Boonen S, Vanderschueren D, Bouillon R, WO’Neill T, Bartfai GF, Casanueva F, Finn JD, Forti G, Giwercman A, Han ST, Huhtaniemi IT, Kula K, Lean EJM, Pendleton N, Punab M, Wu CWF. The EMAS study group. Association of hypogonadism with vitamin D status: the European Male Ageing Study. Eur J Endocrinol 2012; 166: 77-85
• 33 Wehr E, Pilz S, OBoehm B, Marz W, Obermayer-Pietsch B. Association of vitamin D status with serum androgen levels in men. Clinical Endocrinol 2010; 73: 243-248
• 34 Lichtenstein MJ, Yarnell JW, Elwood PC, Beswick AD, Sweetnam PM, Marks V, Teale D, Riad-Fahmy D. Sex hormones, insulin, lipids, and prevalent ischemic heart disease. Am J Epidemiol 1987; 126: 647-657
• 35 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
• 36 Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
• 37 Meinitzer A, Kielstein JT, Pilz S, Drechsler C, Ritz E, Boehm BO, Winkelmann BR, März W. Symmetrical and asymmetrical dimethylarginine as predictors for mortality in patients referred for coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study. Clin Chem 2011; 57: 112-121
• 38 Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 2002; 45: 1609-1616
• 39 Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease will it live up to its hype?. J Am Coll Cardiol 2011; 58: 1547-1556
• 40 Ergür AT, Berberoğlu M, Atasay B, Şıklar Z, Bilir P, Arsan S, Söylemez F, Öcal G. Vitamin D Deficiency in Turkish Mothers and Their Neonates and in Women of Reproductive Age. J Clin Res Ped Endo 2009; 1: 266-269
• 41 Meer IM, Middelkoop BJC, Boeke AJP, Lips P. Prevalence of vitamin D deficiency among Turkish, Moroccan, Indian and sub-Sahara African populations in Europe and their countries of origin: an overview. Osteoporos Int 2011; 22: 1009-1021
• 42 Akpınar P, Icagasıoglu A. The releation between vitamin D and quality of life. Turkish Journal of Osteoporosis 2012; 18: 13-18
• 43 Atli T, Gullu S, Uysal AR, Erdogan G. The prevalence of Vitamin D deficiency and effects of ultraviolet light on Vitamin D levels in elderly Turkish population. Arch Gerontol Geriatr 2005; 40: 53-60